Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 29054911

Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Blood
Publication date
2017 Dec 14
First author
Avet-Loiseau H

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Avet-Loiseau H
      type
      Author
    2. name
      Bahlis NJ
      type
      Author
    3. name
      Chng WJ
      type
      Author
    4. name
      Masszi T
      type
      Author
    5. name
      Viterbo L
      type
      Author
    6. name
      Pour L
      type
      Author
    7. name
      Ganly P
      type
      Author
    8. name
      Palumbo A
      type
      Author
    9. name
      Cavo M
      type
      Author
    10. name
      Langer C
      type
      Author
    11. name
      Pluta A
      type
      Author
    12. name
      Nagler A
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Avet-Loiseau H
      type
      Author
    2. name
      Bahlis NJ
      type
      Author
    3. name
      Chng WJ
      type
      Author
    4. name
      Masszi T
      type
      Author
    5. name
      Viterbo L
      type
      Author
    6. name
      Pour L
      type
      Author
    7. name
      Ganly P
      type
      Author
    8. name
      Palumbo A
      type
      Author
    9. name
      Cavo M
      type
      Author
    10. name
      Langer C
      type
      Author
    11. name
      Pluta A
      type
      Author
    12. name
      Nagler A
      type
      Author
    bibliography ids
    1. nci-bib-d92755a8130a92f2b28fc764
    book metadata
    content sha256
    2305f92528e794486c96a4a7d82a893491549becf3a7960a5b4a676c6bea5319
    document type
    citation
    dois
    1. 10.1182/blood-2017-06-791228
    electronic publication date
    display
    2017 Oct 20
    precision
    day
    year
    2017
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:29054911
    immutable id
    pubmed:29054911@2305f92528e794486c96a4a7d82a893491549becf3a7960a5b4a676c6bea5319
    journal
    abbreviation
    Blood
    issn electronic
    1528-0020
    issn print
    0006-4971
    issue
    24
    name
    Blood
    nlm unique id
    7603509
    pages
    2610-2618
    volume
    130
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      29054911
      provenance
      batch id
      fb25b16edcb1373b70c1
      provider
      NCBI PubMed ESummary
      record sha256
      69a38066cde6705f0d9171325d52a25cdc9758c81c14f70f980924df1fb88915
      response sha256
      182c99bf1974b58308315b66aa28d31c61e8fc31cf3de4cadb0340a4f6734c52
      retrieved at
      2026-09-09T23:47:28.490065+00:00
      publication date
      display
      2017 Dec 14
      precision
      day
      year
      2017
      publication types
      1. Clinical Trial, Phase III
      2. Journal Article
      3. Multicenter Study
      4. Randomized Controlled Trial
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/29054911/
      title
      Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients.

      Preserved source evidence · Not medical advice